Swiss Group for Clinical Cancer Research

🇨🇭Switzerland

Country: 🇨🇭Switzerland

Ownership: Private

Established: 1965-01-01

Employees: -

Market Cap: -

Website: http://www.sakk.ch/

Clinical Trials

Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

Phase 1

Terminated

Conditions: Mantle Cell Lymphoma

Interventions: Drug: Ibrutinib
Drug: bortezomib

First Posted Date: 2015-02-05

Last Posted Date: 2022-03-11

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 58

Registration Number: NCT02356458

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇮🇹
European Institute of Oncology, Milano, Italy
🇨🇭
Kantonsspital - St. Gallen, St. Gallen, Switzerland

and more 16 locations

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Phase 2

Completed

Conditions: Myeloproliferative Neoplasm
Primary Myelofibrosis
Essential Thrombocythemia
Polycythemia Vera

Interventions: Drug: Mirabegron

First Posted Date: 2014-12-08

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 39

Registration Number: NCT02311569

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Inselspital Bern, Bern, Switzerland
🇨🇭
Hopitaux Universitaires de Geneve, Genève 14, Switzerland

and more 8 locations

Impact of a Surgical Sealing Patch on Lymphatic Drainage After ALND for Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: TachoSil® patches

First Posted Date: 2014-12-08

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 142

Registration Number: NCT02311543

Locations: 🇨🇭
Kantonsspital Aarau, Aarau, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, Switzerland

and more 13 locations

Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

Phase 2

Completed

Conditions: Myeloma

Interventions: Drug: Nelfinavir
Drug: bortezomib
Drug: Dexamethasone

First Posted Date: 2014-07-11

Last Posted Date: 2019-06-26

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 34

Registration Number: NCT02188537

Locations: 🇨🇭
Universitaetsspital-Basel, Basel, Switzerland
🇨🇭
Istituto Oncologico Svizzera Italiana IOSI, Bellinzona, Switzerland
🇨🇭
Hopital Fribourgeois, Fribourg, Switzerland

and more 9 locations

CR1447 in Endocrine Responsive-HER2neg and TN-ARpos Breast Cancer

Phase 2

Terminated

Conditions: Breast Cancer
Metastatic Breast Adenocarcinoma

Interventions: Drug: CR1447

First Posted Date: 2014-02-20

Last Posted Date: 2023-06-27

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 29

Registration Number: NCT02067741

Locations: 🇨🇭
Universitätsspital Basel, Basel, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland
🇨🇭
Oncocare / Klinik Engeried, Bern, Switzerland

and more 10 locations

Early Hippocampal Avoidance Prophylactic Cranial Irradiation in Patients With LD SCLC

Not Applicable

Completed

Conditions: Small-Cell Lung Cancer

First Posted Date: 2014-02-07

Last Posted Date: 2020-01-29

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 44

Registration Number: NCT02058056

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Kantonsspital Winterthur, Winterthur, Switzerland
🇨🇭
Hopitaux Universitaires de Geneve, Genève 14, Switzerland

and more 5 locations

Orteronel Maintenance Therapy in Patients With mCRPC Previously Treated With Novel Hormonal Agents

Phase 3

Withdrawn

Conditions: Prostate Cancer

Interventions: Drug: Orteronel
Drug: Placebo

First Posted Date: 2014-02-03

Last Posted Date: 2018-07-30

Lead Sponsor: Swiss Group for Clinical Cancer Research

Registration Number: NCT02053311

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana - Ospedale Regionale Bellinzona e Valli, Bellinzona, Switzerland
🇨🇭
Kantonsspital Luzern, Luzerne, Switzerland
🇨🇭
Kantonsspital Baden, Baden, Switzerland

and more 4 locations

Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks

Phase 3

Active, not recruiting

Conditions: Metastatic Breast Cancer
Metastatic Prostate Cancer
Bone Metastases

Interventions: Drug: Denosumab (standard dosing)
Drug: Denosumab (reduced dosing)

First Posted Date: 2014-01-31

Last Posted Date: 2024-07-22

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 1380

Registration Number: NCT02051218

Locations: 🇦🇹
Landeskrankenhaus Feldkirch, Feldkirch, Austria
🇨🇭
Universitaetsspital Basel, Basel, Switzerland
🇨🇭
Clinique De Genolier, Genolier, Switzerland

and more 46 locations

LDE225 and Paclitaxel in Solid Tumors

Phase 1

Completed

Conditions: Solid Tumor
Ovarian Cancer

Interventions: Drug: LDE225
Drug: Paclitaxel

First Posted Date: 2013-10-01

Last Posted Date: 2019-12-06

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 30

Registration Number: NCT01954355

Locations: 🇨🇭
Istituto Oncologico della Svizzera Italiana, Bellinzona, Switzerland
🇨🇭
Kantonsspital Graubünden, Chur, Switzerland
🇨🇭
Centre Pluridisciplinaire d'Oncologie CHUV, Lausanne, Switzerland

and more 1 locations

Adjuvant Treatment Recommendation and Oncotype DX® in Early Breast Cancer

Completed

Conditions: Breast Cancer

First Posted Date: 2013-08-21

Last Posted Date: 2019-05-15

Lead Sponsor: Swiss Group for Clinical Cancer Research

Target Recruit Count: 229

Registration Number: NCT01926964

Locations: 🇨🇭
Spitalzentrum Biel, Biel, Switzerland
🇨🇭
Kantonsspital Frauenfeld / Brustzentrum Thurgau, Frauenfeld, Switzerland
🇨🇭
Universitaetsspital-Basel, Basel, Switzerland

and more 16 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy